Supplementary Figure 1.



Supplementary Figure 1 (Online Resource 1): Swimmer plot showing treatments given to iMCD-NOS patients in our cohort. All patients who received rituximab were given 4 weekly doses of 375 mg/m². Siltuximab was administered as ongoing therapy at 11 mg/kg every 3 weeks, with the dosing interval extended to every 4–6 weeks in select patients who sustained disease control for >6 months. Other therapies given included IVIG, prednisone, dexamethasone, and cyclophosphamide.